Market closed

ACADIA Pharmaceuticals/$ACAD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Ticker

$ACAD
Trading on

Industry

Biotechnology

Employees

654

ACAD Metrics

BasicAdvanced
$2.7B
12.00
$1.36
0.43
-
$2.7B
0.43
$20.68
$14.15
1.7M
2.376
2.18
5.737
7.095
5.44%
38.89%
12
2.824
3.71
4.43
17.205
31.85%
-463.53%
25.54%
9.15%

What the Analysts think about ACAD

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.

ACAD Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ACAD Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACAD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals (ACAD) has a market cap of $2.7B as of April 03, 2025.

What is the P/E ratio for ACADIA Pharmaceuticals stock?

The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 12 as of April 03, 2025.

Does ACADIA Pharmaceuticals stock pay dividends?

No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of April 03, 2025.

When is the next ACADIA Pharmaceuticals dividend payment date?

ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.

What is the beta indicator for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.